

University of Dundee

ARIA digital anamorphosis

Bousquet, Jean; Anto, Josep M.; Bachert, Claus; Haahtela, Tari; Zuberbier, Torsten; Czarlewski, Wienczysława

Published in:
Allergy

DOI:
[10.1111/all.14422](https://doi.org/10.1111/all.14422)

Publication date:
2021

Licence:
CC BY-NC-ND

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Bousquet, J., Anto, J. M., Bachert, C., Haahtela, T., Zuberbier, T., Czarlewski, W., Bedbrook, A., Bosnic-Anticevich, S., Walter Canonica, G., Cardona, V., Costa, E., Cruz, A. A., Erhola, M., Fokkens, W. J., Fonseca, J. A., Illario, M., Carloslvancevich, J., Jutel, M., Klimek, L., ... Zidarn, M. (2021). ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. *Allergy*, 76(1), 168-190. <https://doi.org/10.1111/all.14422>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Jean Bousquet^{1,2}  | Josep M. Anto^{3,4,5,6} | Claus Bachert⁷  | Tari Haahtela⁸  | Torsten Zuberbier⁹  | Wienczyslawa Czarlewski¹⁰ | Anna Bedbrook¹ | Sinthia Bosnic-Anticevich¹¹ | G. Walter Canonica¹² | Victoria Cardona¹³  | Elisio Costa¹⁴ | Alvaro A. Cruz¹⁵  | Marina Erhola¹⁶ | Wytske J. Fokkens¹⁷  | Joao A. Fonseca¹⁸ | Maddalena Illario¹⁹ | Juan-Carlos Ivancevich²⁰ | Marek Jutel²¹ | Ludger Klimek²² | Piotr Kuna²³ | Violeta Kvedariene²⁴ | LTT Le²⁵ | Désirée E. Larenas-Linnemann²⁶  | Daniel Laune²⁷ | Olga M. Lourenço²⁸  | Erik Melén²⁹ | Joaquim Mullol³⁰  | Marek Niedozytko³¹  | Mikaëla Odemyr³² | Yoshitaka Okamoto³³ | Nikos G. Papadopoulos^{34,35}  | Vincenzo Patella³⁶  | Oliver Pfaar³⁷  | Nhân Pham-Thi³⁸ | Christine Rolland³⁹ | Boleslaw Samolinski⁴⁰ | Aziz Sheikh⁴¹ | Mikhail Sofiev⁴² | Charlotte Suppli Ulrik⁴³ | Ana Todo-Bom⁴⁴ | Peter-Valentin Tomazic⁴⁵  | Sanna Toppila-Salmi⁸  | Ioanna Tsiligianni⁴⁶ | Arunas Valiulis⁴⁷ | Erkka Valovirta⁴⁸ | Maria-Teresa Ventura⁴⁹ | Samantha Walker⁵⁰ | Sian Williams⁵¹ | Arzu Yorgancioglu⁵² | Ioana Agache⁵³  | Cezmi A. Akdis⁵⁴  | Rute Almeida¹⁸ | Ignacio J. Ansotegui⁵⁵ | Isabella Annesi-Maesano⁵⁶ | Sylvie Arnavielhe²⁷ | Xavier Basagaña^{3,4,5,6} | Eric D. Bateman⁵⁷ | Annabelle Bédard^{3,4,5,6} | Martin Bedolla-Barajas⁵⁸ | Sven Becker⁵⁹ | Kazi S. Bennoor⁶⁰ | Samuel Benveniste^{61,62} | Karl C. Bergmann⁹  | Michael Bewick⁶³ | Slawomir Bialek⁶⁴ | Nils E. Billo⁶⁵ | Carsten Bindslev-Jensen⁶⁶ | Leif Bjermer⁶⁷ | Hubert Blain^{68,69} | Matteo Bonini⁷⁰  | Philippe Bonniaud⁷¹ | Isabelle Bosse⁷² | Jacques Bouchard⁷³ | Louis-Philippe Boulet⁷⁴  | Rodolphe Bourret⁷⁵ | Koen Boussey⁷⁶ | Fluvio Braidó⁷⁷ | Vitalis Briedis⁷⁸ | Andrew Briggs⁷⁹ | Christopher E. Brightling⁸⁰ | Jan Brozek⁸¹ | Guy Brusselle⁸² | Luisa Brussino⁸³ | Roland Buhl⁸⁴ | Roland Buonaiuto⁸⁵ | Moises A. Calderon⁸⁶ |

Abbreviations: AIRWAYS-ICPs, integrated care pathways for airway diseases; AIT, allergen immunotherapy; AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; CARAT, Control of Allergic Rhinitis and Asthma Test; CDSS, clinical decision support system; DB-PC-RCT, double-blind, placebo-controlled, randomized trial; EFA, European Federation of Allergy and Airways Diseases Patients' Association; EIP on AHA, European Innovation Partnership on Active and Healthy Ageing; EIT, European Institute for Innovation and Technology; EQ5D, EuroQol; EU, European Union; GA²LEN, Global Allergy and Asthma European network; GARD, Global Alliance against Chronic Respiratory Diseases; GRADE, Grading of Recommendations Assessment, Development and Evaluation; ICP, integrated care pathway; IT, Internet technology; JA-CHRODIS, Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle; MACVIA, fighting chronic diseases for active and healthy ageing; MASK, Mobile Airways Sentinel Network; MASK-air[®] (formerly Allergy Diary); MeDALL, Mechanisms of the Development of Allergy; POLLAR, Impact of air POLLution on Asthma and Rhinitis; QOL, quality of life; RCT, randomized controlled trials; RWD, real-world data; RWE, real-world evidence; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; SMS, symptom-medication score; TRL, technology readiness level; TWINNING, Transfer of Innovation; WHO, World Health Organization.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Paulo Camargos⁸⁷ | Thierry Camuzat⁸⁸ | Luis Caraballo⁸⁹ | Ana-Maria Carriazo⁹⁰ |
 Warner Carr⁹¹ | Christine Cartier⁹² | Thomas Casale⁹³  | Lorenzo Cecchi⁹⁴  |
 Alfonso M. Cepeda Sarabia⁹⁵ | Niels H. Chavannes⁹⁶ | Ekaterine Chkhartishvili⁹⁷ |
 Derek K. Chu⁸¹ | Cemal Cingi⁹⁸  | Jaime Correia de Sousa⁹⁹  | David J. Costa¹⁰⁰ |
 Anne-Lise Courbis¹⁰¹ | Adnan Custovic¹⁰² | Biljana Cvetkoski¹¹ | Gennaro D'Amato¹⁰³  |
 Jane da Silva¹⁰⁴ | Carina Dantas¹⁰⁵ | Dejan Dokic¹⁰⁶ | Yves Dauvilliers¹⁰⁷ |
 Giulia De Feo¹⁰⁸ | Govert De Vries¹⁰⁹ | Philippe Devillier¹¹⁰  | Stefania Di Capua¹¹¹ |
 Gerard Dray¹⁰¹ | Ruta Dubakiene¹¹² | Stephen R. Durham¹¹³  | Mark Dykewicz¹¹⁴ |
 Motohiro Ebisawa¹¹⁵ | Mina Gaga¹¹⁶ | Yehia El-Gamal¹¹⁷ | Enrico Heffler¹²  |
 Regina Emuzyte¹¹⁸ | John Farrell¹¹⁹ | Jean-Luc Fauquet¹²⁰ | Alessandro Fiocchi¹²¹  |
 Antje Fink-Wagner¹²² | Jean-François Fontaine¹²³ | José M. Fuentes Perez¹²⁴  |
 Bilun Gemicioğlu¹²⁵ | Amiran Gamkrelidze¹²⁶ | Judith Garcia-Aymerich³ |
 Philippe Gevaert⁷ | René Maximiliano Gomez¹²⁷ | Sandra González Díaz¹²⁸ |
 Maia Gotua¹²⁹  | Nick A. Guldemon¹³⁰ | Maria-Antonieta Guzmán¹³¹ |
 Jawad Hajjam¹³² | Yunuen R. Huerta Villalobos¹³³ | Marc Humbert¹³⁴ |
 Guido Iaccarino¹³⁵ | Despo Ierodiakonou¹³⁶ | Tomohisa Inuma³³  | Ewa Jassem¹³⁷ |
 Guy Joos⁸² | Ki-Suck Jung¹³⁸ | Igor Kaidashev¹³⁹ | Omer Kalayci¹⁴⁰ |
 Przemyslaw Kardas¹⁴¹ | Thomas Keil¹⁴² | Musa Khaitov¹⁴³ | Nikolai Khaltayev¹⁴⁴ |
 Jorg Kleine-Tebbe¹⁴⁵  | Rostislav Kouznetsov⁴² | Marek L. Kowalski¹⁴⁶  |
 Vicky Kritikos¹¹  | Inger Kull¹⁴⁷  | Stefania La Grutta¹⁴⁸ | Lisa Leonardini¹⁴⁹ |
 Henrik Ljungberg¹⁵⁰ | Philip Lieberman¹⁵¹ | Brian Lipworth¹⁵² |
 Karin C. Lodrup Carlsen¹⁵³  | Catarina Lopes-Pereira¹⁵⁴ | Claudia C. Loureiro¹⁵⁵  |
 Renaud Louis¹⁵⁶ | Alpana Mair¹⁵⁷ | Bassam Mahboub¹⁵⁸ | Michaël Makris¹⁵⁹ |
 Joao Malva¹⁶⁰ | Patrick Manning¹⁶¹ | Gailen D. Marshall¹⁶² | Mohamed R. Masjedi¹⁶³ |
 Jorge F. Maspero¹⁶⁴ | Pedro Carreiro-Martins¹⁶⁵  | Mika Makela⁸ |
 Eve Mathieu-Dupas²⁷ | Marcus Maurer⁹  | Esteban De Manuel Keenoy¹⁶⁶ |
 Elisabete Melo-Gomes¹⁶⁷ | Eli O. Meltzer¹⁶⁸ | Enrica Menditto¹⁶⁹ |
 Jacques Mercier¹⁷⁰ | Yann Micheli²⁷ | Neven Miculnic¹⁷¹ | Florin Mihaltan¹⁷² |
 Branislava Milenkovic¹⁷³ | Dimitirios I. Mitsias³⁵ | Giuliana Moda¹⁷⁴ |
 Maria-Dolores Mogica-Martinez¹⁷⁵ | Yousser Mohammad¹⁷⁶ | Steve Montefort¹⁷⁷ |
 Ricardo Monti⁸³ | Mario Morais-Almeida¹⁷⁸  | Ralph Mösges¹⁷⁹  |
 Lars Münter¹⁸⁰ | Antonella Muraro¹⁸¹ | Ruth Murray¹⁸² | Robert Naclerio¹⁸³ |
 Luigi Napoli¹⁸⁴ | Leyla Namazova-Baranova¹⁸⁵ | Hugo Neffen¹⁸⁶ | Kristoff Nekam¹⁸⁷ |
 Angelo Neou¹⁸⁸ | Björn Nordlund¹⁵⁰ | Ettore Novellino¹⁸⁹ | Dieudonné Nyembue¹⁹⁰ |
 Robyn O'Hehir¹⁹¹ | Ken Ohta³⁵  | Kimi Okubo¹⁹² | Gabrielle L. Onorato¹ |
 Valentina Orlando¹⁸⁹ | Solange Ouedraogo¹⁹³ | Julia Palamarchuk⁴² |
 Isabella Pali-Schöll¹⁹⁴ | Peter Panzner¹⁹⁵ | Hae-Sim Park¹⁹⁶  | Gianni Passalacqua¹⁹⁷  |
 Jean-Louis Pépin¹⁹⁸ | Ema Paulino¹⁹⁹ | Ruby Pawankar²⁰⁰ | Jim Phillips²⁰¹ |

Robert Picard²⁰² | Hilary Pinnock⁴⁰ | Davor Plavec²⁰³ | Todor A. Popov²⁰⁴ |
 Fabienne Portejoie¹ | David Price²⁰⁵  | Emmanuel P. Prokopakis²⁰⁶ |
 Fotis Psarros²⁰⁷ | Benoit Pugin²⁰⁸ | Francesca Puggioni¹² |
 Pablo Quinones-Delgado²⁰⁹ | Filip Raciborski⁴⁰ | Rojin Rajabian-Söderlund²¹⁰ |
 Frederico S. Regateiro⁴⁴ | Sietze Reitsma¹⁷ | Daniela Rivero-Yeverino²¹¹ |
 Graham Roberts²¹²  | Nicolas Roche²¹³ | Erendira Rodriguez-Zagal²¹¹ |
 Christine Rolland³⁹ | Regina E. Roller-Wirnsberger²¹⁴ | Nelson Rosario²¹⁵ |
 Antonino Romano²¹⁶ | Menachem Rottem²¹⁷ | Dermot Ryan²¹⁸  |
 Johanna Salimäki²¹⁹ | Mario M. Sanchez-Borges²²⁰  | Joaquin Sastre²²¹  |
 Glenis K. Scadding²²² | Sophie Scheire⁷⁶ | Peter Schmid-Grendelmeier²²³  |
 Holger J. Schünemann⁸¹ | Faradiba Sarquis Serpa²²⁴ | Mohamed Shamji²²⁵  |
 Juan-Carlos Sisul²²⁶ | Mikhail Sofiev⁴² | Dirceu Solé²²⁷ | David Somekh²²⁸ |
 Talant Sooronbaev²²⁹ | Milan Sova²³⁰ | François Spertini²³¹ | Otto Spranger¹²² |
 Cristiana Stellato¹⁰⁸  | Rafael Stelmach²³² | Michel Thibaudon²³³ | Teresa To²³⁴ |
 Mondher Toumi²³⁵ | Omar Usmani²³⁶ | Antonio A. Valero²³⁷ | Rudolph Valenta^{238,239}  |
 Marylin Valentin-Rostan²⁴⁰ | Marilyn Urrutia Pereira²⁶³ | Rianne van der Kleij²⁴¹ |
 Michiel Van Eerd¹⁰⁹ | Olivier Vandenplas²⁴²  | Tuula Vasankari²⁴³ |
 Antonio Vaz Carneiro²⁴⁴ | Giorgio Vezzani²⁴⁵ | Frédéric Viart⁹² | Giovanni Viegi²⁴⁶ |
 Dana Wallace²⁴⁷ | Martin Wagenmann²⁴⁸  | De Yun Wang²⁴⁹ | Susan Wasserman²⁵⁰ |
 Magnus Wickman²⁵¹ | Dennis M. Williams²⁵² | Gary Wong²⁵³  |
 Piotr Wroczyński²⁵⁴ | Panayiotis K. Yiallourous²⁵⁵ | Osman M. Yusuf²⁵⁶ |
 Heather J. Zar²⁵⁷ | Stéphane Zeng²⁵⁸ | Mario E. Zernotti²⁵⁹ | Luo Zhang²⁶⁰  |
 Nan Shan Zhong²⁶¹ | Mihaela Zidarn²⁶²

¹MACVIA-France and CHU, Montpellier, France

²INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, and Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany

³ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

⁴IMIM (Hospital del Mar Research Institute), Barcelona, Spain

⁵CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

⁶Universitat Pompeu Fabra (UPF), Barcelona, Spain

⁷Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium and Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital Guangzhou, China, and Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm and Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden

⁸Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland

⁹Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Member of GA2LEN, Berlin, Germany

¹⁰Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France

¹¹Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia

¹²Personalized Medicine Clinic Asthma & Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano and Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

¹³Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, Barcelona, Spain

¹⁴UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal

¹⁵ProAR—Núcleo de Excelência em Asma, Federal University of Bahia, Brazil and WHO GARD Planning Group, Brazil

¹⁶National Institute for Health and Welfare, Helsinki, Finland

- ¹⁷Department of Otorhinolaryngology, Academic Medical Centres, AMC, Amsterdam, the Netherlands, and Euforea, Brussels, Belgium
- ¹⁸CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto; and Medida, Lda Porto, Portugal
- ¹⁹Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy
- ²⁰Servicio de Alergia e Inmunología, Clínica Santa Isabel, Buenos Aires, Argentina
- ²¹Department of Clinical Immunology, Wrocław Medical University and ALL-MED Medical Research Institute, Warsaw, Poland
- ²²Center for Rhinology and Allergology, Wiesbaden, Germany
- ²³Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland
- ²⁴Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania
- ²⁵University of Medicine and Pharmacy, Hochiminh City, Vietnam
- ²⁶Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico
- ²⁷KYomed INNOV, Montpellier, France
- ²⁸Faculty of Health Sciences and CICS—UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
- ²⁹Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- ³⁰Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic; Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain
- ³¹Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland
- ³²EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium
- ³³Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan
- ³⁴Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK
- ³⁵Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou", University of Athens, Athens, Greece
- ³⁶Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, "Santa Maria della Speranza" Hospital, Salerno, Italy
- ³⁷Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
- ³⁸Ecole polytechnique, Palaiseau, IRBA (Institut de Recherche bio-Médicale des Armées, Bretigny), France
- ³⁹Association Asthme et Allergie, Paris, France
- ⁴⁰Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
- ⁴¹The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
- ⁴²Finnish Meteorological Institute (FMI), Helsinki, Finland
- ⁴³Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Copenhagen, Denmark
- ⁴⁴Allergy and Clinical Immunology Unit, Institute of Immunology, Faculty of Medicine, University of Coimbra, ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, Coimbra, Portugal
- ⁴⁵Department of General ORL, H&NS, Medical University of Graz, Graz, Austria
- ⁴⁶Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland
- ⁴⁷Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania
- ⁴⁸Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland
- ⁴⁹University of Bari Medical School, Unit of Geriatric Immunoallergy, Bari, Italy
- ⁵⁰Asthma UK, London, UK
- ⁵¹International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland
- ⁵²Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
- ⁵³Faculty of Medicine, Transylvania University, Brasov, Romania
- ⁵⁴Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
- ⁵⁵Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain
- ⁵⁶Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Universités, Medical School Saint Antoine, Paris, France
- ⁵⁷Department of Medicine, University of Cape Town, Cape Town, South Africa
- ⁵⁸Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalajara, Mexico
- ⁵⁹Department of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany
- ⁶⁰Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh
- ⁶¹National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France
- ⁶²Mines ParisTech CRI—PSL Research University, Fontainebleau, France
- ⁶³iQ4U Consultants Ltd, London, UK
- ⁶⁴Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland
- ⁶⁵Independent Consultant, Joensuu, Finland

- ⁶⁶Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark
- ⁶⁷Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden
- ⁶⁸Department of Geriatrics, Montpellier University hospital, Montpellier, France
- ⁶⁹EA 2991, Euromov, University Montpellier, Montpellier, France
- ⁷⁰UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, and National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, UK
- ⁷¹CHU Dijon, Dijon, France
- ⁷²Allergist, La Rochelle, France
- ⁷³Laval's University, Quebec, QC, Canada
- ⁷⁴Quebec Heart and Lung Institute, Laval University, Quebec, QC, Canada
- ⁷⁵Centre Hospitalier Valenciennes, Valenciennes, France
- ⁷⁶Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
- ⁷⁷University of Genoa, Department of Internal Medicine (DiMI) and IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- ⁷⁸Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania
- ⁷⁹Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
- ⁸⁰Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK
- ⁸¹Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, McMaster University, Hamilton, ON, Canada
- ⁸²Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- ⁸³Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy
- ⁸⁴Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
- ⁸⁵Municipality Pharmacy, Sarno, Italy
- ⁸⁶Imperial College London—National Heart and Lung Institute, London, UK
- ⁸⁷Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil
- ⁸⁸Assitant Director General, Montpellier, Région Occitanie, Montpellier, France
- ⁸⁹Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer Piso, Cartagena, Colombia, and Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia
- ⁹⁰Regional Ministry of Health of Andalusia, Seville, Spain
- ⁹¹Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA
- ⁹²ASA—Advanced Solutions Accelerator, Clapiers, France
- ⁹³Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA
- ⁹⁴SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy
- ⁹⁵Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia and SLaa, Sociedad Latinoamericana de Allergia, Asma e Immunologia, Branquilla, Colombia
- ⁹⁶Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
- ⁹⁷Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia
- ⁹⁸ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey
- ⁹⁹Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's, PT Government Associate Laboratory, Guimaraes, Portugal
- ¹⁰⁰General Practice, Nîmes, France
- ¹⁰¹IMT Mines Ales, Université Montpellier, Montpellier, France
- ¹⁰²Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, UK
- ¹⁰³Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital ACardarelli, Napoli, Italy
- ¹⁰⁴Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianópolis-SC, Brazil
- ¹⁰⁵Cáritas Diocesana de Coimbra, Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal
- ¹⁰⁶Medical Faculty Skopje, University Clinic of Pulmology and Allergy, Skopje, Republic of Macedonia
- ¹⁰⁷Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France
- ¹⁰⁸Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
- ¹⁰⁹Peercode BV, Geldermalsen, The Netherlands
- ¹¹⁰UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France
- ¹¹¹Farmacie Dei Golfi Group, Massa Lubrense, Italy
- ¹¹²Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania
- ¹¹³Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, UK

- ¹¹⁴Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA
- ¹¹⁵Clinical Research Center for Allergy and Rheumatology, Sagamiara National Hospital, Sagamiara, Japan
- ¹¹⁶ERS President 2017-2018, Athens Chest Hospital, 7th Resp Med Dept and Asthma Center, Athens, Greece
- ¹¹⁷Pediatric Allergy and Immunology Unit, Children's hospital, Ain Shams University, Cairo, Egypt
- ¹¹⁸Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- ¹¹⁹Department of Health, Social Services and Public Safety, Northern Ireland Belfast, UK
- ¹²⁰CHU Clermont-Ferrand, Unité d'allergologie de l'enfant, pôle pédiatrique, Hôpital Estaing, Clermont-Ferrand, France
- ¹²¹Division of Allergy, Department of Pediatric Medicine—The Bambino Gesù Children's Research Hospital Holy See, Rome, Italy
- ¹²²Global Allergy and Airways Patient Platform GAAPP, Vienna, Austria
- ¹²³Allergist, Reims, France
- ¹²⁴Hospital General Regional 1 "Dr Carlos Mc Gregor Sanchez Navarro" IMSS, Mexico City, Mexico
- ¹²⁵Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
- ¹²⁶Gamkrelidze National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia
- ¹²⁷Allergy & Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina
- ¹²⁸Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico
- ¹²⁹Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia
- ¹³⁰Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, The Netherlands
- ¹³¹Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile
- ¹³²Centich: Centre d'Expertise National des Technologies de l'Information et de la communication pour l'autonomie, Groupe VyV, Conseil Régional des Pays de la Loire, Centre d'expertise Partenariat Européen d'Innovation pour un vieillissement actif et en bonne santé, Nantes, France
- ¹³³IMSS Hospital General Region 1, Dr Carlos Mc Gregor Sanchez Navarro, Mexico City, Mexico
- ¹³⁴Université Paris-Sud; Service de Pneumologie, Hôpital Bicêtre; Inserm UMR_S999, Le Kremlin Bicêtre, France
- ¹³⁵Department of Advanced Biomedical Sciences, Federico II University, Napoli, Italy
- ¹³⁶Department of Social Medicine, Faculty of Medicine, University of Crete, and International Primary Care Respiratory Group, Crete, Greece
- ¹³⁷Department of Allergology, Medical University of Gdańsk, Gdansk, Poland
- ¹³⁸Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea
- ¹³⁹Ukrainina Medical Stomatological Academy, Poltava, Ukraine
- ¹⁴⁰Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey
- ¹⁴¹First Department of Family Medicine, Medical University of Lodz, Poland
- ¹⁴²Institute of Social Medicine, Epidemiology and Health Economics, Charité—Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Würzburg, and Institute of Health Resort Medicine and Health Promotion, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany
- ¹⁴³National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation
- ¹⁴⁴GARD Chairman, Geneva, Switzerland
- ¹⁴⁵Allergy & Asthma Center Westend, Berlin, Germany
- ¹⁴⁶Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland
- ¹⁴⁷Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, and Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
- ¹⁴⁸Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), Palermo, Italy
- ¹⁴⁹Veneto Region, Mattone Internazionale Program, Venice, Italy
- ¹⁵⁰Lung-Allergy Department at Astrid Lindgren Children's Hospital, Karolinska University Hospital, & Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- ¹⁵¹Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, USA
- ¹⁵²Scottish Centre for Respiratory Research, Cardiovascular & Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK
- ¹⁵³Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway
- ¹⁵⁴Market Access Senior Manager, Medicines for Europe, Brussels, Belgium
- ¹⁵⁵Pneumology Department, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- ¹⁵⁶Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium
- ¹⁵⁷DG for Health and Social Care, Scottish Government, Edinburgh, UK
- ¹⁵⁸Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE
- ¹⁵⁹Allergy Unit "D Kalogeromitros", 2nd Department of Dermatology and Venereology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Chaidari, Greece
- ¹⁶⁰Coimbra Institute for Clinical and Biomedical Research (iCIBR), Faculty of Medicine, University of Coimbra; Coimbra, and Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal

- ¹⁶¹Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland
- ¹⁶²Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS, USA
- ¹⁶³Tobacco Control Research Centre; Iranian Anti Tobacco Association, Tehran, Iran
- ¹⁶⁴Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina
- ¹⁶⁵Serviço de Imunologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal and Nova Medical School/Comprehensive Health Research Center (CHRC), Universidade Nova de Lisboa, Lisboa, Portugal
- ¹⁶⁶Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bizkaia, Spain
- ¹⁶⁷PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal
- ¹⁶⁸Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA
- ¹⁶⁹CIRFF, Federico II University, Naples, Italy
- ¹⁷⁰Department of Physiology, CHRU, University Montpellier, Vice President for Research, PhyMedExp, INSERM U1046, CNRS UMR 9214, Montpellier, France
- ¹⁷¹Croatian Pulmonary Society, Zagreb, Croatia
- ¹⁷²National Institute of Pneumology M Nasta, Bucharest, Romania
- ¹⁷³Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia
- ¹⁷⁴Regione Piemonte, Torino, Italy
- ¹⁷⁵Col Jardines de Sta Monica, Tlalnepantla, Mexico
- ¹⁷⁶National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, and Syrian Private University-Damascus, Damascus, Syria
- ¹⁷⁷Lead Respiratory Physician Mater Dei Hospital Malta, Academic Head of Department and Professor of Medicine, University of Malta, Deputy Dean Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta
- ¹⁷⁸Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal
- ¹⁷⁹CRI-Clinical Research International-Ltd, Hamburg, Germany
- ¹⁸⁰Danish Committee for Health Education, Copenhagen East, Denmark
- ¹⁸¹Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy
- ¹⁸²Research Fellow, OPC, Cambridge, UK and Director Medscript, Paraparaumu, New Zealand
- ¹⁸³Johns Hopkins School of Medicine, Baltimore, MD, USA
- ¹⁸⁴Director, Consortium of Pharmacies and Services COSAFER, Salerno, Italy
- ¹⁸⁵Scientific Centre of Children's Health under the PoH, Russian National Research Medical University named Pirogov, Moscow, Russia
- ¹⁸⁶Director of Center of Allergy, Immunology and Respiratory Diseases, Center for Allergy and Immunology, Santa Fe, Argentina
- ¹⁸⁷Hospital of the Hospitalier Brothers in Buda, Budapest, Hungary
- ¹⁸⁸Die Hautambulanz and Rothhaar study center, Berlin, Germany
- ¹⁸⁹Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy
- ¹⁹⁰ENT Department, University Hospital of Kinshasa, Kinshasa, Congo
- ¹⁹¹Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Vic., Australia; Department of Immunology, Monash University, Melbourne, Vic., Australia
- ¹⁹²Department of Otolaryngology, Nippon Medical School, Tokyo, Japan
- ¹⁹³Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso
- ¹⁹⁴Department of Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria
- ¹⁹⁵Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
- ¹⁹⁶Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea
- ¹⁹⁷Allergy and Respiratory Diseases, Ospedale Policlinico San Martino-University of Genoa, Genoa, Italy
- ¹⁹⁸Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, Grenoble, France
- ¹⁹⁹Ezfy, Lisbon, Portugal
- ²⁰⁰Department of Pediatrics, Nippon Medical School, Tokyo, Japan
- ²⁰¹Centre for Empowering Patients and Communities, Falkland, UK
- ²⁰²Conseil Général de l'Economie Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France
- ²⁰³Children's Hospital Srebrnjak, Zagreb, School of Medicine, University JJ Strossmayer, Osijek, Croatia
- ²⁰⁴University Hospital "Sv Ivan Rilski", Sofia, Bulgaria
- ²⁰⁵Observational and Pragmatic Research Institute Singapore, Singapore City, Singapore
- ²⁰⁶Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece
- ²⁰⁷Allergy Department, Athens Naval Hospital, Athens, Greece
- ²⁰⁸European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium
- ²⁰⁹Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain

- ²¹⁰Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden
- ²¹¹Allergist, Mexico City, Mexico
- ²¹²David Hide Centre, St Mary's Hospital, Isle of Wight and University of Southampton, Southampton, UK
- ²¹³Pneumologie et Soins Intensifs Respiratoires, Centre Hôpital Cochin, Hôpitaux Universitaires Paris, Paris, France
- ²¹⁴Department of Internal Medicine, Medical University of Graz, Graz, Austria
- ²¹⁵Hospital de Clinicas, University of Parana, Parana, Brazil
- ²¹⁶Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome and IRCCS Oasi Maria SS, Troina, Italy
- ²¹⁷Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel
- ²¹⁸Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK
- ²¹⁹Association of Finnish Pharmacists, Helsinki, Finland
- ²²⁰Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela
- ²²¹Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
- ²²²The Royal National TNE Hospital, University College, London, UK
- ²²³Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland
- ²²⁴Asthma Reference Center, School of Medicine of Santa Casa de Misericórdia of Vitoria—Esperito Santo, Vitoria, Brazil
- ²²⁵Immunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, Imperial College London, London, UK
- ²²⁶Sociedad Paraguaya de Alergia Asma e Inmunología, Paraguay
- ²²⁷Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil
- ²²⁸European Health Futures Forum (EHFF), Dromahair, UK
- ²²⁹Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan
- ²³⁰Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic
- ²³¹Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- ²³²Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- ²³³RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France
- ²³⁴SickKids Hospital and Institute of Health Policy, Management and Evaluation, Toronto, Canada
- ²³⁵Public Health, Aix-marseille University, Marseille, France
- ²³⁶National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, Airways Disease Section, London, UK
- ²³⁷Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunology, IDIBAPS, University of Barcelona, Barcelona, Spain
- ²³⁸Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
- ²³⁹NRC Institute of Immunology FMBA of Russia, Moscow, Russia and Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
- ²⁴⁰Allergist, Montevideo, Uruguay
- ²⁴¹Department of Public Health & Primary Care, Leiden University Medical Center (LUMC), Leiden, The Netherlands, Erasmus MC, Department of Obstetrics and Gynaecology, University Medical Center, Rotterdam, The Netherlands
- ²⁴²Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium
- ²⁴³FILHA, Finnish Lung Association, Helsinki, and Turku University, Turku, Finland
- ²⁴⁴Instituto de Medicina Preventiva e Saúde Pública, Instituto de Saúde Ambiental, Centro de Estudos de Medicina Baseada na Evidência, Cochrane, Portugal
- ²⁴⁵Pulmonary Unit, Department of Medical Specialties, Arcispedale S Maria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy
- ²⁴⁶Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa (Italy), Via Trieste 41, 56126, Pisa, Italy; and CNR Institute of Biomedicine and Molecular Immunology "A Monroy", Palermo, Italy
- ²⁴⁷Nova Southeastern University, Fort Lauderdale, FL, USA
- ²⁴⁸Department of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- ²⁴⁹Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore
- ²⁵⁰Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada
- ²⁵¹Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden
- ²⁵²Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- ²⁵³Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
- ²⁵⁴Department of Physical Pharmacy and Bioanalysis, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland
- ²⁵⁵Cyprus International Institute for Environmental & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus; Department of Pediatrics, Hospital "Archbishop Makarios III", Nicosia, Cyprus
- ²⁵⁶The Allergy and Asthma Institute, Pakistan
- ²⁵⁷Department of Paediatrics and Child Health, Red Cross Children's Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa
- ²⁵⁸Bull DSAS, Echirolles, France

²⁵⁹Universidad Católica de Córdoba, Córdoba, Argentina

²⁶⁰Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China

²⁶¹State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

²⁶²University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia

²⁶³PIPA Pediatric Program on Asthma Prevention, Uruguaiana, Brazil

Correspondence

Jean Bousquet, MACVIA-France, CHU
Arnaud de Villeneuve, 371 Avenue du Doyen
Gaston Giraud, 34295 Montpellier Cedex 5,
France.
Email: jean.bousquet@orange.fr

Funding information

MASK funding was obtained from EU grants (SPAL, POLLAR, Sunfrail, Rhinitis and Asthma TWINNING, DHE TWINNING on severe asthma), the Région Occitanie (France), unrestricted educational grants (Meda, Mylan, ALK, GSK, Novartis, Sanofi, Stallergènes and Uriach) and private donations. Euforea provided assistance for the ARIA website and the physician's questionnaire.

Abstract

Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.

KEYWORDS

ARIA, asthma, CARAT, digital transformation of health and care, MASK, rhinitis

1 | INTRODUCTION

Anamorphosis—from the Greek *αναμόρφωση*: *transformation*—is used in several fields to describe the transformation of a distorted object (e.g. painting, architecture, entomology, biology). Digital technology reveals the day-to-day experience of patients and provides a new type of information that—when properly collected and interpreted—will restore the real expression of the disease. In this paper, anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies.

The strategic overview (Table 1, Figure 1) and the vision of MASK include several considerations (Table 2). The disease burden and the healthcare costs for people with allergic and chronic respiratory diseases are increasing rapidly.¹ Transformation of the healthcare system for integrated care through leveraging developments in digital health is urgently needed.² The term “digital health” includes advanced medical technologies, disruptive innovations and digital communication tools aiming to provide best practice health care.³ Smart devices and internet-based applications are largely used in airway diseases and are likely to address certain unmet needs.⁴ However, these new tools need to be tested (a) for privacy rules, security and legislation of the Medical Device Regulation (May 2020); (b) for acceptability, usability and cost-effectiveness⁵; and (c) for validity. They should then be evaluated in the frame of the overall digital transformation of health and care, their impact on healthcare delivery as well as health outcomes. mHealth tools and strategies enabling the digital transformation of health and care, empowering citizens and building a healthier society represent a novel important step in health care. However, a practical integrated approach is required.

In 2014, on behalf of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA),⁶ AIRWAYS-ICPs (integrated care pathways for airway diseases) was initiated.^{7,8} The objective was

to launch a collaboration to develop multisectoral care pathways (ICPs) for chronic respiratory diseases in European countries and beyond as a Global Alliance against Chronic Respiratory Diseases (GARD) demonstration project (Figure 1). MASK (Mobile Airways Sentinel Network) is the mHealth strategy of AIRWAYS-ICPs and ARIA.⁹ It was based on the ARIA study group which exists in 92 countries. MASK is deployed in 26 countries and 18 languages. MASK, as a practical ICT integrated approach, was initially developed as an app (MASK-air®) and is now an e-platform for allergic diseases and asthma.

The Control of Allergic Rhinitis and Asthma Test (CARAT) is a patient-reported outcome that assesses the level of control of both asthma and AR using a single tool.¹⁰ It enables the implementation of the ARIA recommendations in the simultaneous assessment and management of both allergic rhinitis (AR) and asthma.¹¹

This paper proposes the ARIA change management strategy in the prevention and management of airway disease.¹² MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It also strengthens ARIA change management. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for each practical step of digital enhancement of care are provided.

2 | DIGITAL TRANSFORMATION OF HEALTH AND CARE IN RHINITIS AND ASTHMA MULTIMORBIDITY

2.1 | The MASK e-platform

MASK, the Phase 3 ARIA (Allergic Rhinitis and its Impact on Asthma) initiative,^{11,13} is a Good Practice of DG Santé for digitally-enabled,

patient-centred care.¹⁴ It has been developed from the MASK-air® app and is a flexible e-platform for allergic diseases and asthma. It includes (a) a freely available app (MASK-air®, formerly the Allergy Diary, Android and iOS),¹³ (b) tools to support healthcare professionals in shared decision-making through an interoperable electronic decision support system (e-CDSS),¹⁵ (c) a web-based interoperable questionnaire for physicians,¹⁶ (d) a questionnaire on asthma and rhinitis (CARAT) for screening allergic diseases and assessing their control and (e) a sentinel network for air quality and pollen seasons. Other tools can be added when needed.

The maturity level of the MASK Good Practice is presented in Tables 1 and 3.

MASK is scaled up using the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) strategy.^{16,25}

2.2 | MASK-air®

2.2.1 | Characteristics

MASK-air® is an ICT (Information and Communication Technology) system centred around the patient.¹⁷ It is operational in 26 countries and 18 languages. It uses a treatment scroll list which includes all of the medications customized for each country. Furthermore, a visual analogue scale (VAS) assesses rhinitis control (global allergy impact, nose, eyes, asthma), sleep and work productivity.^{26,27} MASK-air® is combined with prediction on allergen season and air quality (POLLAR: Impact of POLLution on Asthma and Rhinitis, EIT Health-funded project).²³ MASK is available in 26 countries and

18 languages including some middle-income countries (Table 2). Patients' organizations and scientific societies are involved.

2.2.2 | Privacy, General Data Protection Regulation (GDPR) and Medical Device Regulation (MDR)

The General Data Protection Regulation (GDPR) regulates the processing of personal data in the European Union (EU).^{28,29} MASK-air® follows the five main principles of personal data protection to be respected during the development of the app: purpose, proportionality and relevance, limited retention period, security and confidentiality, as well as the rights of the users regarding management of personal data (including withdrawal and modification).³⁰ Moreover, MASK-air® uses k-anonymity for geolocation.³¹ A double encryption database has been set up.

MASK-air® is currently a Class 1 Medical Device but will be upgraded to Class 2A with the new MDR to be enforced in the EU in May 2021.³²

2.2.3 | Validation

There are absolute prerequisites for the launch of an app. They include the following:

1. The MASK-air® questions have been validated by patients (studies by Madopa and STIMCO, unpublished) and are easily understood by patients in different countries.

TABLE 1 Strategic overview

Acronym	Name	Dates
WHO-associated projects		
ARIA	Allergic Rhinitis and its Impact on Asthma	1999–
WHO Collaborating Center for Rhinitis and Asthma		2004–2014
GARD	Global Alliance against Chronic Respiratory Diseases	2003–
EU grants and projects		
GA ² LEN	Global Allergy and Asthma European Network (FP6)	2004–
MeDALL	Mechanisms of the Development of Allergy (FP7)	2009–2014
Sunfrail		
EIP on AHA	European Innovation Partnership on Active and Healthy Ageing (DG Santé & CONNECT)	2012–2020
TWINNING	Transfer of Innovation	2017–2019
DHE TWINNING	Transfer of innovation in severe asthma (H2020)	2019–2020
Vigour		2019–2021
POLLAR	Impact of Pollution on Asthma and Rhinitis (EIT health)	2018–2019
Good Practice DG Santé on digital health (DG Santé)		2018


Abbreviations: ARIA, Allergic Rhinitis and its Impact on Asthma; CARAT, Control of Allergic Rhinitis and Asthma Test; EAACI, European Academy of Allergy and Clinical Immunology; e-CDSS, electronic clinical decision support system; GA²LEN, Global Allergy and Asthma European Network; GARD, Global Alliance against Chronic Respiratory Diseases; POLLAR, Impact of Pollution on Asthma and Rhinitis; WHO, World Health Organization.

POLICY

Transformation of Health and Care in the Digital Single Market

Chapter 5

"Digital tools for citizen empowerment and for person-centred care"



Differences exist between countries/regions and health care systems

FIGURE 1 Care pathways proposed in the MASK strategy (adapted from Ref. [6])

2. MASK-air[®] has followed the COSMIN (CONsensus-based Standards for the selection of health Measurement INstruments) guidelines.³³
3. The independence of data has been confirmed.²⁴
4. Translations have been validated using a back-translation.
5. MASK-air[®] has been implemented in the different situations in which it is used.^{14,15,17,18,24,30,33–41}

2.3 | CARAT

CARAT is a validated questionnaire that can summarize the clinical status of asthma and rhinitis (multimorbidity) of the previous 4 weeks. It complements the frequent/daily self-assessment in the MASK-air app and the physician's clinical assessment.

2.3.1 | Characteristics

The CARAT questionnaire has two domains - allergic rhinitis and asthma - and 10 items regarding symptoms, sleep, activities and drug use within the past 4 weeks.²⁰ CARAT's minimal clinically important difference can detect change over time (high responsiveness).²¹ CARAT supports shared decisions between the patient and

the physician as well as within the healthcare team. CARAT has been used in 19 countries globally including developing countries.²²

CARAT can be used in a range of different aims: (a) screening of patients with rhinitis or asthma in different settings including pharmacies,⁴² (b) follow-up consultations together with lung function,⁴³ (c) patient self-management⁴⁴ and (d) identifying patients with uncontrolled asthma at pharmacies.⁴² It should increase awareness of the level of disease control and strengthen the partnership between patients and doctors in the management of asthma and rhinitis by helping to define shared treatment goals.

CARAT has been used in epidemiology and clinical research⁴⁵: it has been included in international multicentre studies, such as the technology transfer of innovative practices (TWINNING) project¹⁶ and the observational longitudinal multicentre prospective study, the "@IT2020" study.⁴⁶ CARAT has been implemented as an mHealth tool in several smartphone applications including MASK-air,¹⁷ InspirerMundi,⁴⁷ the Adolescent Adherence Patient Tool (ADAPT) app⁴⁸ and Lung Manager.⁴⁹

2.3.2 | Validation

CARAT has been thoroughly studied in cross-sectional and prospective studies conducted at all levels of MASK Care Pathways. It meets all COSMIN criteria for patient-reported outcome measures.⁵⁰

CARAT has been used in clinical studies and in clinical practice. It has enabled comparison between groups as well as evaluation of individual patients over time.^{10,20} The questionnaire has been deployed in patient care and/or research. CARAT has been implemented in different settings (pharmacies, primary care, secondary care, epidemiology and clinical research) and technologies including mHealth tools,^{17,42,45,47,48,51–53} but also in severe asthma by specialists.⁵⁴

2.3.3 | New functionalities

CARAT has the potential to evolve in order to further strengthen multimorbidity assessment and to focus on more severe patients. This

TABLE 2 Vision of MASK

1. The burden of rhinitis and asthma (multimorbidity) and unmet medical needs are unacceptable and require a novel approach to tackle them
2. Healthcare costs should be sustainable despite the increased prevalence of allergic diseases and the availability of new expensive treatments
3. mHealth should be applied to rhinitis and asthma to reduce unmet medical needs and sustain health care costs
4. A novel approach should embed medical knowledge, patients' needs and mHealth
5. The ultimate goal is change management for rhinitis and asthma

TABLE 3 Maturity level of MASK

MASK achievement	TRL	References
App for rhinitis and multimorbidity (MASK-air®): available in 26 countries, 18 languages, 35 000 users	9	[17–19]
CARAT questionnaire for screening and control of rhinitis and asthma, available in 20 countries	9	[20–22]
e-physician questionnaire for rhinitis (available on the Euforea website) deployed in 23 countries and 17 languages	9	[16]
Embedding air quality (outdoor air pollution) and pollen data in MASK-air® (POLLAR)	9	[23]
e-CDSS for shared decision-making in rhinitis	7	[15]
EAACI-ARIACARE-digital network	8	
Allergy score	7	[24]
Embedding artificial intelligence in MASK-air®	3	

Note: Abbreviations: CARAT, Control of Allergic Rhinitis and Asthma Test; EAACI, European Academy of Allergy and Clinical Immunology; e-CDSS, electronic clinical decision support system; POLLAR, Impact of Pollution on Asthma and Rhinitis.

change can be carried out simply by reassessing questions that were excluded during the initial developing process.¹⁰ In particular, eye symptoms should be included: within the asthma-rhinitis multimorbidity, they are associated with more severe phenotypes as demonstrated by the MASK-air app³⁷ and confirmed by an epidemiologic study with full medical observation.²²

2.4 | Electronic clinical decision support system (eCDSS) for rhinitis

The interoperable electronic decision support system (eCDSS)¹⁵ is based on an algorithm designed by the ARIA expert group and validated using real-world evidence.⁵⁶ This eCDSS is to be used on tablets by pharmacists and physicians.

2.5 | Web-based physician's questionnaire for rhinitis and asthma

An interoperable questionnaire for physicians is available online on the Euforea website (<https://www.euforea.eu>). Around 1,000 patients have been enrolled in the rhinitis-TWINNING using the questionnaire. They are then followed up using the MASK-air® app.¹⁶

2.6 | Sentinel network for air quality and pollen prediction

POLLAR has confirmed the interactions between air pollution, asthma and rhinitis in order to propose the prediction of these environmental factors in MASK-air®.^{23,40} It uses the MASK-air® app combined with a new tool allowing queries on pollen and air quality, in geolocalized patients. Allergic symptoms of the MASK-air® app are integrated with the Symptom Forecasting Model developed within the PASYFO

project of Copernicus Atmospheric Monitoring Service, which also supplies the meteorological, air quality and pollen information for Europe. Additional pollen and global air quality forecasts are generated by the SILAM model of the Finnish Meteorological Institute (FMI).^{56–58} Machine learning will be used to assess the relationship between air pollution, AR and asthma to further refine the prediction.

3 | PATIENTS' VIEWS

Many patients do not understand the needs and benefits of mHealth and may worry about data privacy (Table 3). Thus, the uptake of mHealth is slow. On the other hand, too many patients rely on internet-based information and on untested mHealth solutions. This attitude may have dangerous implications since patients may receive an incorrect diagnosis or management strategy.

3.1 | Features required to satisfy patients

A qualitative study was carried out by MADOPA in 2016 for MASK to better understand the patients' needs and expectations (Table 4).

3.2 | Implementation and communication strategy for patients

Without a communication strategy, the app will not be largely used. However, the communication plan will only be put in place in 2020 once the POLLAR module has been added. Documents are available in 18 languages and can be downloaded from the MASK website (<https://www.mask-air.com>). They include leaflets for patients, physicians and pharmacists as well as other documents. In Mexico, this strategy was found to be effective. It will be deployed to other countries.

TABLE 4 Patients' needs and expectations of an mHealth app

A. Problems patients encounter using an app			
Fear of using an app (particularly in elderly patients)			
Customer loyalty problems (young adult patients)			
Not willing to use one app regularly			
Changing the app frequently			
Not understanding how to fill in the app			
Not understanding or caring about what must be done (e.g. seeing a physician), despite clear results/instructions provided by the app			
Not feeling ill (usually males)			
Feeling too ill and filling in the app too much (females, some males also)			
B. Patients' expectations			
Patients' expectations	Existing feature in MASK	To be added to MASK	
		Feature	Expected
Advice to modify the treatment	Simple advice exists in line with the GDPR	More sophisticated advice will be ready with Medical Device Regulation (MDR) Class 2A	06-2021 ^a
Pollen and pollution		POLLAR	06-2020
Visualization of control and medications	Existing but poorly found by patients and physicians	More user friendly and better information	06-2020
Help science to better understand the disease in order to get future benefits	Existing		

Abbreviations: GDPR, General Data Protection Regulation; MASK, Mobile Airway Sentinel Network; POLLAR, Impact of Pollution on Asthma and Rhinitis.

^aDue to new regulation not yet published.

The communication strategy must involve local patients' organizations. It will be deployed with the patients' organization EFA. The importance of patients' associations has always been recognized in ARIA. For the digital transformation of health and care, they are even more important. The following messages sent by the app need to be reinforced for the patients:

1. Better understanding the symptoms.
2. Sentinel network linking aerobiology data and control.
3. Improved adherence.
4. Self-management.
5. Patient empowerment.

4 | MASK ACHIEVEMENTS IN DIGITAL ANAMORPHOSIS

4.1 | Anamorphosis steps based on digital learning and Real-World Data

MASK-air[®] has been in use for 5 years and has evolved since its first inception. Major RWD results of the MASK strategy (MASK-air[®], POLLAR and CARAT) are presented in Table 5.

4.2 | Health outcomes

In AR and asthma, a relevant outcome providing information on the cost-effectiveness of interventions is needed. EQ-5D (EuroQol), a standardized and validated non-disease-specific instrument used to describe and value health-related quality of life, has been used in allergic rhinitis^{36,69-74} but it cannot be used for daily assessment. EQ-5D is one of the MASK-air[®] questionnaires.³⁶ In MASK, VAS work correlates with other MASK outcomes (VAS global, nose, eye and asthma)^{24,34} and should be considered as a potentially useful allergic rhinitis outcome in intervention studies.

RWD make health technology assessment possible.

4.3 | Use of real-world data to develop next-generation care pathways for chronic respiratory diseases

Care pathways are structured multi-disciplinary care plans detailing the key steps of patient care.⁷ They promote the translation of guideline recommendations into local protocols and their application to clinical practice. ICPs have been proposed with a focus on mHealth technologies that should enhance self-management and adherence to guidelines and ICPs.

TABLE 5 ARIA anamorphosis steps for the digital transformation of health and care in airway diseases towards change management

A*	Areas of innovation	Novel findings using RWD	Solutions for digital health	References
Innovation in phenotypes				
1	Allergic phenotypes (based on epidemiologic evidence)	MASK <ul style="list-style-type: none"> found novel phenotypes of rhinitis, conjunctivitis and asthma. suggested that a "severe phenotype" exists proposing a new stratification of allergic patients for optimized treatment. These findings were confirmed in classical epidemiologic studies 	A novel approach of multimorbidity is needed to select and stratify patients using artificial intelligence	[37] [59–63]
Innovation in diagnosis				
2	Diagnosis	Using the CARAT questionnaire: <ul style="list-style-type: none"> Highly motivated and experienced allergists misdiagnose asthma and conjunctivitis in patients with rhinitis. They have a different approach to assess severity. 	The CARAT questionnaire is in MASK-air® and can be used in the physician's waiting room to help in the diagnosis of allergic diseases and to initiate the stratification of patients	Submitted
Innovation in management				
3	Adherence to treatment	<ul style="list-style-type: none"> Patients often self-medicate and use OTC medications Patients do not follow the physician's prescription This attitude accords with the allergic physician's behaviour 	Poor adherence of patients to treatment indicating that RCTs carried out in adherent patients do not reflect real life and that change management is needed with a new registration of medications (prn) Need to change practice and medication registration	[37,39]
4	Novel approach for efficacy assessment	<ul style="list-style-type: none"> MASK shows that patients receiving co-medications are less well controlled than those receiving no treatment or single treatment. These observations are in contradistinction with guidelines. Patients do not follow guidelines or the physician's prescriptions. They self-medicate. Next-generation guidelines are needed. Chamber studies confirm the speed of onset of some treatments 	Guidelines assume that patients follow the doctor's orders. Adherence to medication is turned to partnership using novel models of education (IT)	[17,19,37] [63]
5	The same tool is used for RCTs, RWD, chamber studies and clinical practice	A symptom-medication score (SMS) based on MASK has been set up and can be used for all purposes	<ul style="list-style-type: none"> Assessment of SMS in RCTs, observational studies, chamber challenges and clinical practice. Direct comparison of RCTs, observational studies, chamber challenges with RWD in patients. Patient stratification for expensive treatments. 	
Health outcomes				
6	Health outcomes and impact	<ul style="list-style-type: none"> There is a significant correlation between VAS work and VAS for global symptoms, nose, eye or asthma. Daily VAS work can be used for economic studies 	<ul style="list-style-type: none"> Work productivity EQ5D Impact (sleep) 	[34–36,38,65]
Next-generation care pathways				
7	Next-generation care pathways	<ul style="list-style-type: none"> Care pathways differ from guidelines Self-care Pharmacist Physician Patients 	Next-generation care pathways are needed <ul style="list-style-type: none"> To account for real-world evidence To provide a holistic view of management and prevention of allergic symptoms and diseases 	[19,55,65–68] [41]

(Continues)

TABLE 5 (Continued)

A*	Areas of innovation	Novel findings using RWD	Solutions for digital health	References
8	Air pollution	<ul style="list-style-type: none"> Air pollution impacts the severity of rhinitis. Prediction of pollution and the pollen season (POLLAR) 	<ul style="list-style-type: none"> Embedding in MASK-air® current data and 3-day prediction for pollen season and air quality. Alerts for peaks of pollen and pollution. 	[23,40]
Centres of excellence in digital health				
9	Centres of Excellence	ARIACARE digital is a novel network with the aim to implement the digital transformation of health and care in airway diseases	<ul style="list-style-type: none"> ARIACARE digital 	
Transfer of innovation				
10	Rhinitis-TWINNING	Completed (but still ongoing) TWINNING in rhinitis and asthma	<ul style="list-style-type: none"> Web-based physician's questionnaire MASK-air® combined 	[16,68]
11	Asthma-TWINNING	DHE TWINNING in severe asthma	<ul style="list-style-type: none"> Asthma-e-platform MASK-air® with asthma combined ARIACARE-Digital 	
Digital transformation of health and care to sustain planetary health				
12	POLLAR	<ul style="list-style-type: none"> Impact of climate change, air pollution and biodiversity 	<ul style="list-style-type: none"> Climate change 	[23,40]
13	Finland's EU Presidency meeting, December 3-4, 2019	<ul style="list-style-type: none"> Care pathways for rhinitis and/or asthma can be used as a model for all chronic diseases. 	<ul style="list-style-type: none"> The way to the digital transformation of health to sustain planetary health 	Bousquet et al., in preparation [104]

Note: A*: anamorphosis.

Abbreviations: CARAT: Control of Allergic Rhinitis and Asthma Test, DHE: DigitalHealthEurope, EQ5D: EuroQuol, MASK: Mobile Airway Sentinel NetworkK, RCT: randomized control trial, RWD: real-world data, TWINNING: Transfer of Innovation, VAS: visual analogue scale.

Next-generation care pathways for airway diseases follow the 2014 AIRWAYS integrated care pathways (ICPs) concept (Figures 1 and 2).⁵⁵ As a proof of concept for chronic disease care, RWD obtained from MASK provide a framework for real-life ICPs centred around the patient with rhinitis, using the mHealth monitoring of environmental exposure. This is implemented in collaboration with professional and patient organizations.

ARIA is constantly evolving and its most recent advance was determined following a meeting of experts/stakeholders in Paris in December 2018^{75,76} (Table 6). Three aspects of care pathways were developed during this meeting: (a) patient participation, health literacy and self-care through technology-assisted "patient activation", (b) implementation of care pathways by pharmacists⁶⁵ and (c) next-generation guidelines assessing the recommendations of GRADE (*Grading of Recommendations, Assessment, Development and Evaluation*) guidelines in rhinitis and asthma using RWE⁵⁵ and AIT.⁶⁶ Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed using existing GRADE-based guidelines,⁷⁷⁻⁷⁹ RWD provided by mHealth Apps^{19,37,39} and additive studies (allergen chamber studies⁶³) to refine the MACVIA algorithm.

4.4 | Network of centres of excellence in digital health

ARIA was established 20 years ago and includes more than 600 members in over 80 countries. In ARIA Phase 4 (change

management for airways diseases), a network of centres of excellence has been organized. GA²LEN ARIACARE is one of the GA²LEN centres of excellence⁸⁴ and includes urticaria care (UCARE)⁸⁵ and atopic dermatitis care (ADCARE). Accreditation follows the UCARE proposals.

ARIACARE digital is a novel network with the aim to implement the digital transformation of health and care in airway diseases. Both members of MASK and others can join the network. ARIACARE-Digital has links with GA²LEN but is a separate entity.

4.5 | Transfer of innovation (TWINNING)

4.5.1 | Rhinitis-Asthma TWINNING

A transfer of innovative practices (TWINNING)^{16,68} was performed with the aim to transfer and implement MASK-air®. The "Organization transferring the innovative practice" (originator organization) had the experience and know-how developed in rhinitis and asthma IT solutions. The "Organization adopting the innovative practice" (receiving/adopter organization) received the innovative practice and implemented it in its territory. The rhinitis TWINNING was deployed from MASK to 22 countries. Around 1,000 patients were enrolled in the study. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly were compared using validated information and

communication technology (ICT) tools (i.e. MASK-air[®], CARAT and a physician's questionnaire developed for the TWINNING). This improved the understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. The TWINNING was selected as a success story.

4.5.2 | DigitalHealthEurope (DHE) Severe Asthma TWINNING

In order to reduce the burden of severe asthma with a focus on old age people, the objectives of the transfer of innovation (DHE Severe Asthma TWINNING) are as follows:

1. To form a European network for severe asthma in old age people globally (this does not currently exist);
2. To better understand the phenotype and treatment of severe asthma with possible differences between countries, age and gender;
3. To include the results into the MASK Good Practice for disease stratification and personalized health care with a vision to optimizing the prescription of expensive treatments (biologics) and following up the patients using RWD;
4. To be the basis for a further deployment beyond the funding, including a network of centres of excellence on severe asthma (ARIACARE and ARIACARE digital).

The DHE TWINNING on SA (Project acronym: H2020, DigitalHealthEurope Grant Agreement Number: 826 353, Project full title: *Support to a Digital Health and Care Innovation initiative*

in the context of Digital Single Market strategy, Call identifier: SC1-HCC-05-2018) was accepted on 16 September 2019.

5 | ONGOING AND FUTURE MASK ACTIONS

5.1 | Advance capabilities: The same IT tool from epidemiologic studies to clinical trials and clinical practice

Symptom-medication scores (SMSs) are needed to investigate the effect of AR treatments, in particular allergen immunotherapy.⁸⁶ Several scores have been proposed and the European Academy of Allergy and Clinical Immunology has designed one.⁸⁷ However, a recent MASK analysis²⁴ has found that this commonly used SMS is not very well correlated with VAS work used as an end point. When considering MASK data,¹⁹ it is possible that some patients with very high levels of VAS global (and work) may not be able to be controlled with current pharmacologic treatments, and a new SMS has been proposed. This SMS for rhinitis has been validated with MASK-air[®] data. Other artificial intelligence analyses are being carried out to obtain an optimal score.

Real-world evidence (RWE) combines results of double-blind, placebo-controlled, randomized trials (DB-PC-RCT) and RWD. However, observational studies provide clinically relevant information in addition to DB-PC-RCT.^{19,37,39} RWD can provide new insights into disease patterns and help improve the safety and effectiveness of health interventions. The same SMS will allow the comparison of the results of DB-PC-RCTs and RWD in population




FIGURE 2 Next-generation ARIA care pathways. AIT: allergen immunotherapy (adapted from ref.14)

TABLE 6 Papers of next-generation care pathways in the digital transformation of health and care

	Title	Journal	Publication
1	From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity	Eur Respir J	[9]
2	Mobile technology in allergic rhinitis: evolution in management or revolution in health and care?	JACI Practice	[5]
3	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases	CTA	[80]
4	2018 Good Practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma <i>Practice presented during the Steering Group on Promotion and Prevention marketplace workshop on "digitally-enabled, integrated, person-centred care" best practices on 12-13 December 2018 in the premises of the Joint Research Centre in Ispra, Italy</i>	CTA	[14]
5	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases (Meeting Report. Part 1)	J Thorac Dis	[75]
6	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases (Meeting Report. Part 2)	J Thorac Dis	[76]
7	ARIA pharmacy 2018: "Allergic rhinitis care pathways for community pharmacy"	Allergy	[65]
9	ARIA Care pathways for allergen-specific immunotherapy following the ARIA recommendations to fill gaps in knowledge ⁸¹	Allergy	[66]
10	ARIA-EAACI Care pathways for allergen-specific immunotherapy Pocket Guide		
11	Next-generation ARIA guidelines for allergic rhinitis based on GRADE and real-world evidence, validating the management algorithm, following GRADE recommendations ^{77,78,82} and chamber studies ^{63,83}	JACI	[80]
12	Digital transformation of health and care in asthma	Allergy	
13	2020 DHE TWINNING on severe asthma		
14	Uniform stratification of severe chronic diseases in adults using mobile technology: App-MM		
15	ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology	JACI	[12]

Note: App-MM: App for multimorbidity, ARIA: Allergic Rhinitis and its Impact on Asthma, CARAT: Control of Allergic Rhinitis and Asthma Test, CTA: Clinical and Translational Allergy, DHE: DigitalHealthEurope, EAACI: European Academy of Allergy and Clinical Immunology, JACI: Journal of Allergy and Clinical Immunology, TWINNING: Transfer of Innovation

studies or for the individual patient.⁸⁰ This will provide complementary information to DB-PC-RCTs and a real-life approach. Since patients are using the app and the same system, it will be possible—using machine learning—to target the efficacy of AIT at the individual level and to propose automatic advice to the physician for the indication of AIT as well as an early stopping rule in clinical practice.⁶⁶

Patient stratification is an important step for expensive treatments such as allergen immunotherapy in allergic diseases or biologics in severe asthma. There are currently no validated genetic or blood biomarkers for predicting or monitoring the efficacy of treatments at an individual patient level in allergic diseases.⁸⁸ mHealth biomarkers (SMS)⁶⁶ and eCDSS¹⁵ may change the scope of AIT in allergic diseases or biologics in asthma or chronic rhinosinusitis.

5.2 | Towards severe asthma

The lessons learnt by MASK will be used to build MASK-asthma which will include (a) a standardized assessment of severity and control, (b) the development of an upgraded e-platform for severe asthma including screening, assessment by physicians and follow-up, (c) the analysis of MASK-air[®] data on file for asthma, (d) a pan-European

IT-based alert system for exacerbations, (e) MASK-asthma IT tools for registries and databases, (f) transfer of innovation, (g) a digital network of centres of excellence (ARIACARE-Digital) and (h) the development of next-generation care pathways for severe asthma.

5.3 | United perspective for chronic diseases to sustain planetary health

Planetary health refers to "the health of human civilization and the state of the natural systems on which it depends".⁸⁹ Most risk factors for noncommunicable diseases (NCDs) are associated with planetary health.

Digital tools can also empower patients in the context of the UN sustainable development goals and in particular regarding those related to sustainability and natural resources.⁹⁰ Future apps in AR could consider providing information to promote behavioural changes that could reduce the planetary impacts of human activity.

During a conference entitled "Europe That Protects: Safeguarding Our Planet, Safeguarding Our Health" - co-organized by the Finnish Institute for Health and Welfare, the Finnish Environment Institute and the European Commission under the auspices of Finland's Presidency of the EU in 2019 - a symposium was held to better understand the digital transformation of health

and care to sustain planetary health in airway diseases. The Finnish Allergy Programme is a proof of concept of planetary health, and MASK (Mobile Airways Sentinel Network), a Good Practice of DG Santé on digitally-enabled, patient-centred care pathways, is in line with the objectives of this programme.

Lessons learnt in rhinitis and asthma multimorbidity¹⁷ can be deployed to other NCDs for change management in health care. A uniform approach can be used¹² for the development of next-generation care pathways in chronic diseases embedding the risk factors involved in planetary health.

This perspective is global since planetary health needs to be tackled in all countries. The World Health Organization and the International Telecommunication Union recognize the importance of mHealth globally, and particularly in developing countries.⁵

5.4 | Value-added medicines: The example of the combination of intra-nasal antihistamine and corticosteroid used as needed

Value-added medicines represent the concept of drug repurposing.⁹¹ They are medicines based on known molecules that address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers. MASK is a proof of concept of drug repurposing as it suggests the importance of as-needed treatment for AR. Value-added medicines are medicines based on known molecules that address healthcare needs,^{8,13,17} and deliver relevant improvement for patients,^{18,37,63,92} healthcare professionals^{18,37} and payers.^{34–36,38} They contribute to addressing unmet patient needs, moving from a tailored and patient's specific approach. By answering patients' unmet needs, they represent a new horizon for those who are currently looking forward to a better quality of life with their treatment.

6 | CONTRIBUTION OF MASK TO THE EU DIGITAL SINGLE MARKET

The Digital Single Market (<https://ec.europa.eu/digital-single-market/en>), part of the Digital Agenda for Europe 2020 programme of the EU, includes three "pillars": (a) access to online products and services, (b) conditions for digital networks and services and (c) growth of the European digital economy. MASK is involved in this strategy by (a) the management of care process, (b) digital networks (ARIACARE-digital network), (c) innovation to market (I2M) to foster the cross-border adoption of digitally-driven marketable solutions, (d) the political, organizational, technological and financial readiness, (e) the contribution to European co-operation and transferability, (f) and the contribution to the European Digital Transformation of Health and Care (Bousquet et al., submitted).

The digital transformation of health and care can improve the quality of health services and ultimately people's health and well-being as well as the economy, in line with EIT Health. In the context of implementing communication on the digital transformation of health and care, DG SANTE, in collaboration with the EU Commission Expert Group "Steering

Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases" (<https://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3622>), scaled up good practices in the field of digitally-enabled, integrated, patient-centred care. MASK was one of the nine Good Practices selected, along with chronic disease and Parkinson's disease.¹⁴

7 | POLITICAL AGENDA

In the severe Asthma TWINNING, the engagement through the Salerno local health agency of ProMIS@Campania network⁶⁸ will ensure that adoption is progressively achieved through a multicentric scale-up pilot. The good practice will then be scaled up to other Italian regions through the National ProMIS network.⁹³

The EU political agenda is of great importance in supporting the digital transformation of health and care for chronic respiratory diseases. The Polish Presidency of the EU Council (2011) prioritized the early diagnosis, prevention and control of chronic respiratory diseases in children.⁹⁴ AIRWAYS-ICPs (integrated care pathways for airway diseases),⁷ initiated in 2014 by the EIP on AHA,^{6,8} launched a collaboration to develop multisectoral ICPs. It was a GARD⁹⁵ demonstration project.⁹⁶

Euforea (European Forum for Research and Education in Allergy and Airway Diseases) proposed a yearly stepwise strategy at the EU or ministerial levels.^{97–99} Euforea organized an EU Summit in Vilnius, Lithuania (March 2018) to propose multisectoral ICPs embedding guided self-management, mHealth and air pollution in chronic respiratory diseases.¹⁰⁰

POLLAR (Impact of air POLLution on Asthma and Rhinitis, EIT Health) is focussing on the impact of allergens and air pollution on airway diseases to propose novel ICPs integrating pollution, sleep and patient literacy.²³ AQuAS, the Catalonia Health Agency, is involved in POLLAR.

8 | CHANGE MANAGEMENT

ARIA phase 4 focusses on change management with the aim of providing an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle—whatever their gender or socio-economic status—in order to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter¹⁰¹ to assess and implement the impact of rhinitis on asthma multimorbidity and to propose multimorbid guidelines.¹² A second change management strategy is proposed by ARIA Phase 4 on the digital transformation of health and care.

9 | CONCLUSION: TOWARDS A REVOLUTION IN RHINITIS AND ASTHMA MANAGEMENT

The MASK strategy represents a proof of concept for other chronic diseases, as asthma-rhinitis multimorbidity plays a key role

in understanding asthma and can be used as a general model of multimorbidity. Moreover, asthma and rhinitis have a life-course approach, whereas most chronic diseases start early in life but are only clinically evident in adulthood. The lessons learnt by the MASK strategy are therefore transposable to other chronic diseases.

Anamorphosis is a metaphor for reimagining and expanding on appearances and overcoming otherness. MASK digital anamorphosis makes it possible to look at data from a different angle. The data then appear to be different to their familiar, expected and/or generally accepted form. Anamorphosis may be associated with fear as phenomenological otherness often accompanies new technology. Education for a better appraisal of mHealth by all stakeholders is therefore essential. Metaphorical language can facilitate communication and shape of thought, thus providing key challenges and opportunities for future research.

mHealth has the potential to profoundly impact health care.¹⁰² mHealth apps now represent an important evolution of health and care for allergic rhinitis and asthma multimorbidity. The digital revolution is underway for rhinitis and asthma.⁵ Innovative health strategies and services will change management⁶ and create a new kind of partnership between the patients, the healthcare providers and the health system.

CONFLICT OF INTEREST

MA reports personal fees from POCI-01-0145-FEDER-029130 mINSPIRERS—mHealth to measure and improve adherence to medication in chronic obstructive respiratory diseases—generalization and evaluation of gamification, peer support and advanced image processing technologies from ERDF (European Regional Development Fund) funded by the COMPETE2020 and by National Funds through FCT (Fundação para a Ciência e a Tecnologia). EB reports personal fees from Novartis, Menarini, ALK, Sanofi Regeneron, Boehringer Ingelheim, AstraZeneca, Sanofi Genzyme, Orion, and is a member of the Science Committee and Board of the Global Initiative for Asthma (GINA). PB reports personal fees and other from Roche, Boehringer and Novartis, personal fees from AstraZeneca and TEVA, and other from Chiesi and Stallergenes. LPB reports research grants for participation to multicentre studies from AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi and Takeda, support for research projects introduced by the investigator from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Takeda, fee for consulting and advisory boards from AstraZeneca, Novartis and Methapharm, nonprofit grants for production of educational materials from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Novartis, conference fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis, and support for participation in conferences and meetings from Novartis and Takeda. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi Aventis, Takeda, Teva, and Uriach, and other from KYomed INNOV. RB reports personal fees from AstraZeneca, Chiesi, Cipla, Sanofi and Teva, grants and personal fees from Boehringer Ingelheim, Novartis

and Roche, and grants from GlaxoSmithKline, all outside the submitted work. VC reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermo Fisher and Stallergenes. JCS reports other from Boehringer Ingelheim, GSK, personal fees, nonfinancial support and other from AstraZeneca, personal fees and other from Mundipharma. AC reports personal fees from Novartis, Regeneron, Thermo Fisher Scientific, Philips and Sanofi. ME reports personal fees from DBV Technologies and Mylan. JF reports being a partner in a company developing mobile technologies for monitoring airways diseases. EH reports personal fees from AstraZeneca, Novartis, GSK, Sanofi Genzyme, Teva, Circassia and Nestlé Purina. GI is consultant for Amicus Therapeutics and received a research grant from Amicus therapeutics. PK reports personal fees from Aflofarm, Fresenius, Lek-AM, Novartis, Polpharma and Sandoz, grants from European Union, European Commission. LK reports personal fees from Allergopharma, HAL Allergie, ALK-Abelló, LETI Pharma, Allergy Therapeutics, Stallergenes, Quintiles, AstraZeneca, GSK, ASIT biotech and Lofarma, and grants and personal fees from MEDA/Mylan and Sanofi. DLL reports personal fees from Armstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried and UCB, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim and Chiesi. RL reports grants and personal fees from GSK, from AZ and Novartis and grants from Chiesi. Dr Loureiro reports personal fees from AstraZeneca, Novartis, GSK, Sanofi, TEVA and Menarini. JM reports personal fees and nonfinancial support from Novartis, Sanofi, AstraZeneca and Immunotek. MM reports grants and personal fees from Aralez, AstraZeneca, FAES, Genentech, Novartis, MSD, Roche, Sanofi, UCB and Uriach. JM reports personal fees from ALK-Abelló, Sanofi Genzyme & Regeneron, Menarini Group, MSD, Mitsubishi-Tanabe, Novartis, UCB Pharma, and GENENTECH—Roche, grants and personal fees from URIACH Group, MYLAN-MEDA Pharma. AM reports personal fees from Aimmune, DVB, Nestlé Health Institute and Nestlé Purina. BN reports other from Co-founded AsthmaTuner, eHealth system for asthma. YO reports personal fees from Kyowa Co., Ltd, Eizai Co., Ltd, Shionogi Co., Ltd., Torii Co., Ltd., GSK and MSD, grants and personal fees from Kyorin Co., Ltd., and Tiho Co., Ltd., grants from Yakuruto Co., Ltd., and Yamada Bee Farm. NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, Sanofi, Mylan/Meda, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH and Boehringer Ingelheim, and grants from Gerolymatos International SA and Capricare. JLP reports grants and personal fees from Air Liquide Foundation, Agiradom, AstraZeneca, Philips and ResMed, grants from Fisher and Paykel, Mutualia and Vitalaire, personal fees from Boehringer Ingelheim, Jazz pharmaceutical, Night Balance and Sefam. DP reports personal fees, nonfinancial support and other from Revenio, grants and personal fees from GlaxoSmithKline, personal fees from Merck and Sandoz, other from Boehringer Ingelheim, Novartis, MSD and Chiesi, nonfinancial support from Menarini, nonfinancial support from Pharmas, and personal fees and nonfinancial support from Salveo. DP reports personal fees from Amgen, Mundipharma, Novartis, Pfizer, Regeneron

Pharmaceuticals, Cipla, GlaxoSmithKline, Kyorin and Thermo Fisher, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia and Mylan, grants from Respiratory Effectiveness Group, Sanofi Genzyme, Teva and Theravance, grants from UK National Health Service, nonfinancial support from Efficacy and Evaluation Mechanism Programme, Health Technology Assessment and stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, and owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore). FP has been scientific consultant, researcher and speaker supported by the following commercial companies: Menarini, Alk-Abello, Almirall, Allergy Therapeutics, Anallergo, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Hal Allergy, Lab. Guidotti, Lofarma, Malesci, MSD, Mundipharma, Novartis, Roche, Sanofi, Stallergenes and Valea. Dr Sastre is consultant for Thermo Fisher, Hycor, Novartis, Sanofi, Leti, Mundipharma, ALK and GSK, paid conferences from Novartis, GSK, Circassia, Sanofi, LETI and FAES FARMA, and research grants from Thermo Fisher, Mundipharma, ALK, Sanofi. GS reports personal fees from ALK, Mylan and ALK and other from Rhinology & Laryngology Research Fund, BSACI and EAACI. MS reports fees from ASIT Biotech.sa, ALK and Allergopharma. AMTB reports grants and personal fees from Novartis, Sanofi, Mundipharma, GSK (GlaxoSmithKline) and Teva Pharma, personal fees from AstraZeneca, grants from Boehringer Ingelheim, outside the submitted work. IT reports personal fees from Honoraria for educational activities, speaking engagements, advisory boards from Boehringer Ingelheim, Astra Zeneca, GSK and Novartis and grants from GSK Hellas and Elpen. MW reports personal fees from ALK-Abello, AstraZeneca, Bencard Allergie, HAL Allergy, Leti Pharma, Meda Pharma, Novartis, Sanofi Aventis, Stallergenes and Teva. SW reports personal fees and other from CSL Behring, Shire, AstraZeneca, Teva, Meda, Merck, GSK and Novartis, personal fees from Pediapharm, Aralez, Sanofi and Stallergenes. The other authors have no conflict of interest to declare.

ORCID

Jean Bousquet  <https://orcid.org/0000-0002-4061-4766>
 Claus Bachert  <https://orcid.org/0000-0003-4742-1665>
 Tari Haahtela  <https://orcid.org/0000-0003-4757-2156>
 Torsten Zuberbier  <https://orcid.org/0000-0002-1466-8875>
 Victoria Cardona  <https://orcid.org/0000-0003-2197-9767>
 Alvaro A. Cruz  <https://orcid.org/0000-0002-7403-3871>
 Wytse J. Fokkens  <https://orcid.org/0000-0003-4852-229X>
 Desiree Larenas-Linnemann  <https://orcid.org/0000-0002-5713-5331>
 Olga M. Lourenço  <https://orcid.org/0000-0002-8401-5976>
 Joaquim Mullol  <https://orcid.org/0000-0003-3463-5007>
 Marek Niedostrytko  <https://orcid.org/0000-0003-1089-1911>
 Nikos G. Papadopoulos  <https://orcid.org/0000-0002-4448-3468>
 Vincenzo Patella  <https://orcid.org/0000-0001-5640-6446>
 Oliver Pfaar  <https://orcid.org/0000-0003-4374-9639>

Peter-Valentin Tomazic  <https://orcid.org/0000-0001-6445-4800>
 Sanna Toppila-Salmi  <https://orcid.org/0000-0003-0890-6686>
 Ioana Agache  <https://orcid.org/0000-0001-7994-364X>
 Cezmi A. Akdis  <https://orcid.org/0000-0001-8020-019X>
 Karl C. Bergmann  <https://orcid.org/0000-0002-0306-9922>
 Matteo Bonini  <https://orcid.org/0000-0002-3042-0765>
 Louis-Philippe Boulet  <https://orcid.org/0000-0003-3485-9393>
 Thomas Casale  <https://orcid.org/0000-0002-3149-7377>
 Lorenzo Cecchi  <https://orcid.org/0000-0002-0658-2449>
 Cemal Cingi  <https://orcid.org/0000-0003-3934-5092>
 Jaime Correia de Sousa  <https://orcid.org/0000-0001-6459-7908>
 Gennaro D'Amato  <https://orcid.org/0000-0002-0503-9428>
 Philippe Devillier  <https://orcid.org/0000-0001-6054-1886>
 Stephen R. Durham  <https://orcid.org/0000-0001-5264-6207>
 Enrico Heffler  <https://orcid.org/0000-0002-0492-5663>
 Alessandro Fiocchi  <https://orcid.org/0000-0002-2549-0523>
 José M. Fuentes Perez  <https://orcid.org/0000-0002-5378-3956>
 Maia Gotua  <https://orcid.org/0000-0003-2497-4128>
 Tomohisa Iinuma  <https://orcid.org/0000-0002-9940-5520>
 Jorg Kleine-Tebbe  <https://orcid.org/0000-0002-2862-7353>
 Marek L. Kowalski  <https://orcid.org/0000-0002-8442-2774>
 Vicky Kritikos  <https://orcid.org/0000-0003-3955-0002>
 Inger Kull  <https://orcid.org/0000-0001-6096-3771>
 Karin C. Lodrup Carlsen  <https://orcid.org/0000-0002-9257-1198>
 Claudia C. Loureiro  <https://orcid.org/0000-0003-0438-6126>
 Pedro Carreiro-Martins  <https://orcid.org/0000-0002-4129-133X>
 Marcus Maurer  <https://orcid.org/0000-0002-4121-481X>
 Mario Morais-Almeida  <https://orcid.org/0000-0003-1837-2980>
 Ralph Mösges  <https://orcid.org/0000-0002-1928-810X>
 Ken Ohta  <https://orcid.org/0000-0001-9734-4579>
 Hae-Sim Park  <https://orcid.org/0000-0003-2614-0303>
 Gianni Passalacqua  <https://orcid.org/0000-0002-5139-3604>
 David Price  <https://orcid.org/0000-0002-9728-9992>
 Graham Roberts  <https://orcid.org/0000-0003-2252-1248>
 Dermot Ryan  <https://orcid.org/0000-0002-4115-7376>
 Mario M. Sanchez-Borges  <https://orcid.org/0000-0002-9308-6418>
 Joaquin Sastre  <https://orcid.org/0000-0003-4689-6837>
 Peter Schmid-Grendelmeier  <https://orcid.org/0000-0003-3215-3370>
 Mohamed Shamji  <https://orcid.org/0000-0003-3425-3463>
 Cristiana Stellato  <https://orcid.org/0000-0002-1294-8355>
 Rudolph Valenta  <https://orcid.org/0000-0001-5944-3365>
 Olivier Vandenplas  <https://orcid.org/0000-0002-4608-3310>
 Martin Wagenmann  <https://orcid.org/0000-0002-9734-0241>
 Gary Wong  <https://orcid.org/0000-0001-5939-812X>
 Luo Zhang  <https://orcid.org/0000-0002-0910-9884>

REFERENCES

1. Zuberbier T, Lotvall J, Simoons S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. *Allergy* 2014;69(10):1275-1279.

2. Gopal G, Suter-Crazzolaro C, Toldo L, Eberhardt W. Digital transformation in healthcare—architectures of present and future information technologies. *Clin Chem Lab Med*. 2019;57(3):328-335.
3. Mesko B, Drobni Z, Benyei E, Gergely B, Gyorffy Z. Digital health is a cultural transformation of traditional healthcare. *Mhealth*. 2017;3:38.
4. Bousquet J, Chavannes NH, Guldemond N, Haahtela T, Hellings PW, Sheikh A. Realising the potential of mHealth to improve asthma and allergy care: how to shape the future. *Eur Respir J*. 2017;49(5):1601966. <https://doi.org/10.1183/13993003.01966-2016>
5. Bousquet J, Ansotegui IJ, Anto JM, et al. Mobile technology in allergic rhinitis: evolution in management or revolution in health and care? *J Allergy Clin Immunol Pract*. 2019;7(8):2511-2533.
6. Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The European innovation partnership on active and healthy ageing: the European geriatric medicine introduces the EIP on AHA column. *Eur Geriatr Med*. 2014;5(6):361-362.
7. Bousquet J, Addis A, Adcock I, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). *Eur Respir J*. 2014;44(2):304-323.
8. Bousquet J, Barbara C, Bateman E, et al. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. *Eur Respir J*. 2016;47(4):1028-1033.
9. Bousquet J, Anto JM, Bachert C, et al. From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. *Eur Respir J*. 2019;54(6):1901023.
10. Nogueira-Silva L, Martins SV, Cruz-Correia R, et al. Control of allergic rhinitis and asthma test—a formal approach to the development of a measuring tool. *Respir Res*. 2009;10:52.
11. Bousquet J, Khaltav N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 2008;63(Suppl 86):8-160.
12. Bousquet J, Hellings PW, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology. *J Allergy Clin Immunol*. 2019;143(3):864-879.
13. Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy*. 2016;6:47.
14. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. *Clin Transl Allergy*. 2019;9:16.
15. Courbis A-L, Murray RB, Arnavielhe S, et al. Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS. *Clin Exp Allergy*. 2018;48(12):1640-1653.
16. Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA)—EIP on AHA TWINNING Reference Site (GARD research demonstration project). *Allergy* 2018;73(1):77-92.
17. Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clin Transl Allergy*. 2018;8:45.
18. Bousquet J, Devillier P, Anto JM, et al. Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study. *Allergy* 2018;73(8):1622-1631.
19. Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: the MASK study. *J Allergy Clin Immunol*. 2019;144(1):135-143.e6.
20. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;65(8):1042-1048.
21. van der Leeuw S, van der Molen T, Dekhuijzen PNR, et al. The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): cross-cultural validation and relation with pollen counts. *NPJ Prim Care Respir Med*. 2015;25:14107.
22. Azevedo P, Correia-de-Sousa J, Bousquet J, et al. Control of Allergic Rhinitis and Asthma Test (CARAT): dissemination and applications in primary care. *Prim Care Respir J*. 2013;22(1):112-116.
23. Bousquet J, Anto JM, Annesi-Maesano I, et al. POLLAR: impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. *Clin Transl Allergy*. 2018;8:36.
24. Bedard A, Anto JM, Fonseca JA, et al. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air(R) App. *Allergy*. 2020;75:1672-1688.
25. Bousquet J, Farrell J, Crooks G, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). *Clin Transl Allergy*. 2016;6:29.
26. Hellings PW, Muraro A, Fokkens W, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. *Clin Transl Allergy*. 2015;5:36.
27. Klimek L, Bergmann K-C, Biedermann T, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOHC). *Allergo J Int*. 2017;26(1):16-24.
28. Recital 26-EU GDPR. EU general data protection regulation 2016/679.2016; <https://doi.org/10.1111/all.14204> [Epub ahead of print]
29. Article 4 EU GDPR. EU general data protection regulation 2016/679 (GDPR). <http://www.privacy-regulation.eu/en/article-4-definitions-GDPR.htm>; 2016.
30. Laune D, Arnavielhe S, Viart F, et al. Application du Règlement Général sur la Protection des Données (RGPD) à une application mobile pour la rhinite et l'asthme (MASK-air). *Rev Mal Resp*. 2019;36(9):1019-1031.
31. Samreth D, Arnavielhe S, Ingenrieth F, et al. Geolocation with respect to personal privacy for the Allergy Diary app—a MASK study. *World Allergy Organ J*. 2018;11(1):15.
32. EU Medical Device regulation. 1/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32017R0745;2017>.
33. Caimmi D, Baiz N, Tanno LK, et al. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. *Clin Exp Allergy*. 2017;47(12):1526-1533.
34. Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: The MASK pilot study. *Allergy* 2017;72(10):1475-1484.
35. Bousquet J, Caimmi DP, Bedbrook A, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. *Allergy* 2017;72(6):857-865.
36. Bousquet J, Arnavielhe S, Bedbrook A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. *Allergy* 2018;73(2):505-510.
37. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. *Allergy* 2018;73(9):1763-1774.
38. Bousquet J, VandenPlas O, Bewick M, et al. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) questionnaire using mobile technology: The MASK study. *J Investig Allergol Clin Immunol*. 2018;28(1):42-44.

39. Menditto E, Costa E, Midao L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK study. *Clin Exp Allergy*. 2019;49(4):442-460.
40. Bédard A, Sofiev M, Arnavielhe S, et al. Interactions between air pollution and pollen season for rhinitis using mobile technology: a MASK-POLLAR study. *J Allergy Clin Immunol Pract*. 2020;8(3):1063-1073.e4.
41. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol*. 2020;145(1):70-80.e3.
42. Lourenco O, Calado S, Sá-Sousa A, Fonseca J. Evaluation of allergic rhinitis and asthma control in a Portuguese community pharmacy setting. *J Manag Care Spec Pharm*. 2014;20(5):513-522.
43. Amaral L, Martins C, Coimbra A. Use of the Control of Allergic Rhinitis and Asthma Test and pulmonary function tests to assess asthma control in pregnancy. *Aust N Z J Obstet Gynaecol*. 2018;58(1):86-90.
44. Kuipers E, Wensing M, de Smet P, Teichert M. Self-management research of asthma and good drug use (SMARAGD study): a pilot trial. *Int J Clin Pharm*. 2017;39(4):888-896.
45. Sá-Sousa A, Amaral R, Morais-Almeida M, et al. Asthma control in the Portuguese National Asthma Survey. *Rev Port Pneumol* 2006;2015(21):209-213.
46. Component Resolved Diagnostics (CRD) and mHealth for Pollen Allergy in Southern Europe. (IT-2020-MC). <https://clinicaltrials.gov/ct2/show/NCT03636919>; 2020.
47. Flokstra-de Blok B, Baretta H, Fonseca J, et al. An app to measure and improve adherence to inhaled treatment. *Proc Int Conf e-Health*. 2017;2017:135-139.
48. Kosse RC, Bouvy ML, de Vries TW, et al. mHealth intervention to support asthma self-management in adolescents: the ADAPT study. *Patient Prefer Adherence*. 2017;11:571-577.
49. Flokstra-de Blok BMJ, Baretta H-J, Fonseca JA, et al. Control of Allergic Rhinitis and Asthma Test with 1-week recall: validation of paper and electronic version. *Allergy* 2018;73(12):2381-2385.
50. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. *J Clin Epidemiol*. 2010;63(7):737-745.
51. Burnay E, Cruz-Correia R, Jacinto T, Sousa AS, Fonseca J. Challenges of a mobile application for asthma and allergic rhinitis patient enablement-interface and synchronization. *Telemed J E Health*. 2013;19(1):13-18.
52. Kosse RC, Bouvy ML, Belitser SV, de Vries TW, van der Wal PS, Koster ES. Effective engagement of adolescent asthma patients with mobile health-supporting medication adherence. *JMIR mHealth uHealth*. 2019;7(3):e12411.
53. Gani F, Lombardi C, Barrocu L, et al. The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. *Clin Mol Allergy*. 2018;16:4.
54. Sousa AS, Pereira AM, Fonseca JA, et al. Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal. *Rev Port Pneumol* (2006). 2015;pii:S2173-5115(15)00080-9
55. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. *J Allergy Clin Immunol*. 2016;138(2):367-374.e2.
56. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol*. 2019.
57. Sofiev M, Vira J, Kouznetsov R, Prank M, Soares J, Genikhovich E. Construction of the SILAM Eulerian atmospheric dispersion model based on the advection algorithm of Michael Galperin. *Geosci Model Dev* 2015;8(11):3497-3522.
58. Sofiev M. On impact of transport conditions on variability of the seasonal pollen index. *Aerobiologia (Bologna)*. 2017;33(1):167-179.
59. Ritenberga O, Sofiev M, Siljamo P, et al. A statistical model for predicting the inter-annual variability of birch pollen abundance in Northern and North-Eastern Europe. *Sci Total Environ*. 2018;615:228-239.
60. Amaral R, Bousquet J, Pereira AM, et al. Disentangling the heterogeneity of allergic respiratory diseases by latent class analysis reveals novel phenotypes. *Allergy* 2019;74(4):698-708.
61. Raciborski F, Bousquet J, Namysłowski A, et al. Correction to: Dissociating polysensitization and multimorbidity in children and adults from a Polish general population cohort. *Clin Transl Allergy*. 2019;9:23.
62. Siroux V, Boudier A, Nadif R, Lupinek C, Valenta R, Bousquet J. Association between asthma, rhinitis, and conjunctivitis multimorbidities with molecular IgE sensitization in adults. *Allergy* 2019;74(4):824-827.
63. Toppila-Salmi S, Chanoine S, Karjalainen J, Pekkanen J, Bousquet J, Siroux V. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. *Allergy*. 2019;74(12):2406-2416.
64. Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. *J Allergy Clin Immunol Pract*. 2018;6(5):1726-1732.
65. Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of rhinitis on work productivity. A systematic review. *J Allergy Clin Immunol Pract*. 2018;6(4):1274-1286.e9.
66. Bosnic-Anticevich S, Costa E, Menditto E, et al. ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Sante) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project. *Allergy* 2019;74(7):1219-1236.
67. Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. *Allergy* 2019;74(11):2087-2102.
68. Bousquet JJ, Schunemann HJ, Togias A, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. *Clin Transl Allergy*. 2019;9:44.
69. Patella V, Florio G, Magliacane D, et al. Prevention Plans to manage climate change and respiratory allergic diseases. Innovative models used in Campania Region (Italy): the TWINNING aria implementation and the allergy safe tree decalogue. *Transl Med UniSa*. 2019;19:95-102.
70. Poole CD, Bannister CA, Andreassen JN, Andersen JS, Currie CJ. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. *Health Qual Life Outcomes*. 2014;12:99.
71. Soler R, de la Hoz B, Badia X, et al. Validation of the Spanish version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). *Rev Clin Esp*. 2004;204(3):131-138.
72. Hoehle LP, Speth MM, Phillips KM, et al. Association between symptoms of allergic rhinitis with decreased general health-related quality of life. *Am J Rhinol Allergy*. 2017;31(4):235-239.
73. Hwang TY, Kim SK, Kim SH, Kim M. A cross sectional survey on health-related quality of life among parents of children with allergic symptoms using the EQ-5D-5L. *J Asthma*. 2019;56(11):1-7.
74. Ilyina N, Edin A, Astafieva N, et al. Efficacy of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, delivered in a single spray, for the treatment of seasonal Allergic Rhinitis: results from Russia. *Int Arch Allergy Immunol*. 2019;178(3):255-263.

75. Speth MM, Hoehle LP, Phillips KM, Caradonna DS, Gray ST, Sedaghat AR. Treatment history and association between allergic rhinitis symptoms and quality of life. *Ir J Med Sci*. 2019;188(2):703-710.
76. Bousquet J, Pham-Thi N, Bedbrook A, et al. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). *J Thorac Dis*. 2019;11(8):3633-3642.
77. Bousquet J, Pham-Thi N, Bedbrook A, et al. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2). *J Thorac Dis*. 2019;11(9):4072-4084.
78. Brożek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol*. 2010;126(3):466-476.
79. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines—2016 revision. *J Allergy Clin Immunol*. 2017;140(4):950-958.
80. Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic treatment of seasonal Allergic Rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. *Ann Intern Med*. 2017;177(12):876-881.
81. Bousquet J, Schünemann H, Togias A, et al. Next-generation ARIA guidelines for allergic rhinitis based on GRADE and real-world evidence. *J Allergy Clin Immunol*. 2020;145(1):70-80.e3. <https://doi.org/10.1016/j.jaci.2019.06.049>. Epub 2019 Oct 15.
82. Calderon MA, Demoly P, Casale T, et al. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project. *Clin Transl Allergy*. 2016;6:41.
83. Wallace DV, Dykewicz MS. Seasonal Allergic Rhinitis: a focused systematic review and practice parameter update. *Curr Opin Allergy Clin Immunol*. 2017;17(4):286-294.
84. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. *Ann Allergy Asthma Immunol*. 2019;122(2):160-166.e1.
85. Bousquet J, Burney PG, Zuberbier T, et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. *Allergy* 2009;64(7):969-977.
86. Maurer M, Metz M, Bindslev-Jensen C, et al. Definition, aims, and implementation of GA(2)LEN Urticaria Centers of reference and excellence. *Allergy* 2016;71:1210-1218.
87. Godicke V, Hundt F. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. *Allergy* 2010;65(12):1499-1505.
88. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. *Allergy* 2014;69(7):854-867.
89. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. *Allergy* 2017;72(8):1156-1173.
90. Whitmee S, Haines A, Beyrer C, et al. Safeguarding human health in the Anthropocene epoch: report of The Rockefeller Foundation-Lancet Commission on planetary health. *Lancet* 2015;386(10007):1973-2028.
91. Konduri N, Aboagye-Nyame F, Mabirizi D, et al. Digital health technologies to support access to medicines and pharmaceutical services in the achievement of sustainable development goals. *Digit Health*. 2018;4:2055207618771407.
92. Toumi M, Remuzat C. Value added medicines: what value repurposed medicines might bring to society? *J Mark Access Health Policy*. 2017;5(1):1264717.
93. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. *Clin Transl Allergy*. 2018;8:25.
94. Bousquet J, Illario M, Farrell J, et al. The reference site collaborative network of the European innovation partnership on active and healthy ageing. *Transl Med UniSa*. 2019;19:66-81.
95. Samolinski B, Fronczak A, Włodarczyk A, Bousquet J. Council of the European Union conclusions on chronic respiratory diseases in children. *Lancet* 2012;379(9822):e45-e46.
96. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. *Allergy* 2007;62(3):216-223.
97. Global Alliance against Chronic Respiratory Diseases (GARD). 9th General Meeting, 14–16 August 2014, Salvador, Brazil. WHO/NMH/MND/CPM/14.1. www.who.int. 2014.
98. Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - a EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. *Allergy* 2017;72(9):1297-1305.
99. Hellings PW, Borrelli D, Pietikainen S, et al. European summit on the prevention and self-management of chronic respiratory diseases: report of the European Union Parliament Summit (29 March 2017). *Clin Transl Allergy*. 2017;7:49.
100. Muraro A, Fokkens WJ, Pietikainen S, et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). *Rhinology*. 2015;53(4):303-307.
101. Valiulis A, Bousquet J, Veryga A, et al. Vilnius declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases. *Clin Transl Allergy*. 2019;9:7.
102. Kotter J. *Leading change*. Boston, MA: Harvard Business School Press; 1996.
103. Ozdalga E, Ozdalga A, Ahuja N. The smartphone in medicine: a review of current and potential use among physicians and students. *J Med Internet Res*. 2012;14(5):e128.
104. Bousquet J, Anto JM, Haahela T, Jousilahti P, Erhola M, Basagana X, et al. Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases-POLLAR symposium under the auspices of Finland's Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WHO), demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. *Clin Transl Allergy*. 2020;10:24.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Bousquet J, Anto JM, Bachert C, et al. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. *Allergy*. 2021;76:168–190. <https://doi.org/10.1111/all.14422>